About Cangene
Cangene is a company based in Rockville (United States) founded in 1998 was acquired by Emergent BioSolutions in December 2013. Cangene operates in a competitive market with competitors including BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
- Headquarter Rockville, United States
- SectorsHealthcare
- Website cangene.com
- Social LinkedIn
- Acquired by Emergent BioSolutions (Dec 2013)
- Investors
- Acquired byEmergent BioSolutions
(Dec 2013)
Investors in Cangene
Cangene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Emergent BioSolutions.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Vaccines for viral infections are developed by the company. | 1998 | emergentbiosolutions.com | Gaithersburg, United States |
Investor details for Cangene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cangene
2 dated milestones of Cangene across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Cangene is founded.
- Exit Acquired by Emergent BioSolutions.
Competitors of Cangene
Cangene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| alxoncology.com | 2015 | Burlingame, United States | $123.02M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| strandtx.com | 2017 | Cambridge, United States | $103.14M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| ventyxbio.com | 2018 | Encinitas, United States | $165.3M | 79 | Therapeutics for autoimmune diseases are developed by the company. | |
| drenbio.com | 2019 | San Carlos, United States | $131M | – | Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases. |
Detailed competitors of Cangene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cangene
Complete news archive for Cangene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cangene
10 companies that operate in the same segment as Cangene (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cangene
Cangene was founded in 1998.
Cangene is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Cangene was founded in 1998 and focused on biopharmaceuticals, particularly hyperimmunes and biodefense products. Operations included plasma-based antitoxins for anthrax, botulism, and vaccinia, with three items held in the U.S. Strategic National Stockpile. Manufacturing facilities were maintained in Winnipeg and Baltimore, alongside a plasma collection site in Winnipeg. Acquisition by Emergent BioSolutions occurred in 2013, relocating headquarters to Rockville, United States.
Cangene's top competitors include Moderna, BeiGene and Strand Therapeutics.
Cangene has 1 investor. Key investors include Emergent BioSolutions.
Yes. Cangene was acquired by Emergent BioSolutions in December 2013.